Emerging Microbes and Infections (Dec 2023)
Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China
- Hongqin Xu,
- Hongyan Li,
- Hailong You,
- Peng Zhang,
- Nan Li,
- Nan Jiang,
- Yang Cao,
- Ling Qin,
- Guixiang Qin,
- Hongbo Qu,
- Heyuan Wang,
- Bo Zou,
- Xia He,
- Dan Li,
- Huazhong Zhao,
- Gang Huang,
- Yang Li,
- Hefeng Zhang,
- Liping Zhu,
- Hongmei Qiao,
- Hongjun Li,
- Shurong Liu,
- Lina Gu,
- Guidong Yin,
- Ye Hu,
- Songbai Xu,
- Weiying Guo,
- Nanya Wang,
- Chaoying Liu,
- Pujun Gao,
- Jie Cao,
- Yang Zheng,
- Kaiyu Zhang,
- Yang Wang,
- Hui Chen,
- Jian Zhang,
- Dongmei Mu,
- Junqi Niu
Affiliations
- Hongqin Xu
- Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Hongyan Li
- Nursing Department, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Hailong You
- Department of Pediatrics, First Hospital of Jilin University, Changchun, People’s Republic of China
- Peng Zhang
- Department of Infectious Diseases, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Nan Li
- Intensive Care Unit, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Nan Jiang
- Department of Infectious Diseases, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Yang Cao
- Department of obstetrics and gynecology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Ling Qin
- Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Guixiang Qin
- Center of Tubercular Meningitis, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Hongbo Qu
- Department of Medical Affairs, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Heyuan Wang
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Bo Zou
- Department of Medical Affairs, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Xia He
- Nursing Department, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Dan Li
- Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Huazhong Zhao
- Department of Integrated Traditional and Western Medicine, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Gang Huang
- Center of Information and Statistics, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Yang Li
- Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Hefeng Zhang
- Department of Integrated Traditional and Western Medicine, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Liping Zhu
- Department of Integrated Traditional and Western Medicine, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Hongmei Qiao
- Department of pediatric respiratory medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Hongjun Li
- The Fifth treatment area, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Shurong Liu
- Department of Hepatology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Lina Gu
- Intensive Care Unit, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Guidong Yin
- Department of cerebral surgery, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Ye Hu
- Department of Hepatology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Songbai Xu
- Department of Neurosurgery, the First Hospital of Jilin University, Changchun, People’s Republic of China
- Weiying Guo
- Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Nanya Wang
- Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Chaoying Liu
- Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Pujun Gao
- Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Jie Cao
- Department of Neology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Yang Zheng
- Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Kaiyu Zhang
- Department of Infectious Diseases, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Yang Wang
- Department of Infectious Diseases, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Hui Chen
- Department of Hepatology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of China
- Jian Zhang
- Department of Infectious Diseases, Changchun Infectious Disease Hospital, Changchun, People’s Republic of China
- Dongmei Mu
- Department of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- Junqi Niu
- Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of China
- DOI
- https://doi.org/10.1080/22221751.2022.2149935
- Journal volume & issue
-
Vol. 12,
no. 1
Abstract
ABSTRACTIt is critical to determine the real-world performance of vaccines against coronavirus disease 2019 (COVID-19) so that appropriate treatments and policies can be implemented. There was a rapid wave of infections by the Omicron variant in Jilin Province (China) during spring 2022. We examined the effectiveness of inactivated vaccines against Omicron using real-world data from this epidemic. This retrospective case-case study of vaccine effectiveness (VE) examined infected patients who were quarantined and treated from April 16 to June 8, 2022 and responded to an electronic questionnaire. Data were analyzed by univariable and multivariable analyses. A total of 2968 cases with SARS-CoV-2 infections (asymptomatic: 1061, mild disease: 1763, pneumonia: 126, severe disease: 18) were enrolled in the study. Multivariable regression indicated that the risk for pneumonia or severe disease was greater in those who were older or had underlying diseases, but was less in those who received COVID-19 vaccines. Relative to no vaccination, VE against the composite of pneumonia and severe disease was significant for those who received 2 doses (60.1%, 95%CI: 40.0%, 73.5%) or 3 doses (68.1%, 95%CI: 44.6%, 81.7%), and VE was similar in the subgroups of males and females. However, VE against the composite of all three classes of symptomatic diseases was not significant overall, nor after stratification by sex. There was no statistical difference in the VE of vaccines from different manufacturers. The inactivated COVID-19 vaccines protected patients against pneumonia and severe disease from Omicron infection, and booster vaccination enhanced this effect.
Keywords
